NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 12, 2024. All figures are in Canadian dollars, unless otherwise noted.

The results of the director elections were as follows:

Name	Votes in Favour	% Votes in Favour	Votes Withheld	% Votes Withheld
Jolyon Burton	16,926,658	99.28%	122,000	0.72%
Daniel Chicoine	16,926,658	99.28%	122,000	0.72%
Sasha Cucuz	16,921,658	99.26%	127,000	0.74%
Dan Legault	16,926,658	99.28%	122,000	0.72%
Joseph Walewicz	16,926,658	99.28%	122,000	0.72%

The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, and (ii) to approve the Company’s amended and restated stock option plan in the form attached as Schedule “A” to the management information circular dated April 23, 2024 prepared in connection with the Meeting.

About NeuPath

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.